RT @swethaann23: IV Golimumab efficacy and Early (ED) vs Late (LD) AS âï¸ED better response than LD with PRO âï¸
Tweet Content
IV Golimumab efficacy and Early (ED) vs Late (LD) AS
⭐️ED better response than LD with PRO
⭐️Treatment-emergent adverse events/ serious adverse 🔼 LD as compared to ED
Abst #0912 #ACR21 @RheumNow https://t.co/5EaWAvfQ57
Show on Archive Page
On
Display in Search Results
On
PDQ
Off